Lastly, leukocyte immunoglobulin-like receptor B3 (LILRB3), a myeloid immune checkpoint, shows increased expression in the myeloid cell compartment of TP53-mutated MDS/AML. This evidence concerns the gene TP53 and myelodysplastic syndrome.